Adaptix announces CEO transition
Our medical imaging technology associate company Adaptix Limited announced today the departure of Chief Executive Officer, Mark Evans. He will be succeeded by interim CEO, Sarah Small and Willem Baralt, the current Chair of the Board, who will be more actively involved in the company on a day-to-day basis.
Willem stated “On Behalf of the Board I would like to thank Mark for the tremendous leadership he has brought to the company as Co-founder and CEO. His drive and vision were instrumental in getting the company to where it is today. We wish him well in his future endeavours.”
Sarah has served Adaptix since 2017, mostly recently heading up finance and leading the Senior Leadership Team as VP Finance and Executive Board Director. Sarah is a Chartered Accountant with over 20 years’ experience of leading financial functions, including C-level experience within an AIM listed company .
Calum McLean, a Non-Executive Director at Adaptix commented “I have been very impressed by the entire senior leadership team at Adaptix. Sarah was a natural fit to take on the interim CEO position. She is as an active member of the Board with proven leadership skills. Her positive influence on the entire team at Adaptix made her the ideal choice to lead the company during this time of transition. We would also like to thank Willem who will also be taking an active role in managing the company and fundraising.”
About Adaptix Limited
Adaptix Limited is transforming radiology through the development of innovative 3D imaging technologies that are significantly better, safer, smaller, and more affordable than traditional radiology systems. At the core of their patent portfolio and commercialization strategy is a distributed Flat Panel X-ray Source (FPS) system which has applications across a multitude of global markets that are currently limited to 2D X-ray imaging systems where cost, speed to diagnostic result, location or dose concerns mean CT is not optimal. Adaptix’s central mission is to transform radiology by offering affordable low-dose 3D imaging at the point-of-care and allowing “3D-first” as the standard of care.
